Skip to main content

ALX Oncology Holdings Inc

corporate_fare Company Profile

ALX Oncology Holdings Inc

ALXO·NASDAQ·Life Sciences·CIK 0001810182

We are a clinical-stage biotechnology company focused on developing new therapies to treat cancer and extend patients' lives. Our clinical pipeline includes two product candidates: evorpacept, a CD47 blocker, and ALX2004, an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC). Our primary product candidate, evorpacept, is designed to be a foundational therapy for immuno-oncology in patients whose cancer over-expresses CD47. Evorpacept is currently being evaluated in the Phase 2 ASPEN-09-Breast clinical trial in combination with trastuzumab and chemotherapy for patients with metastatic HER2-positive breast cancer. It is also being studied in clinical trials with other targeted anti-cancer antibodies. Cancer cells use CD47, a cell surface protein, as a "don't eat me" signal to avoid being engulfed by macrophages. We are developing evorpacept as a next-generation checkpoint inhibitor with a high affinity for CD47, aiming to avoid the blood-related toxicities seen with other CD47 blocking methods. Our second pipeline candidate, ALX2004, is a new EGFR-targeted antibody-drug conjugate with a distinct mechanism of action, which entered a Phase 1 clinical trial in August 2025.

ALX Oncology Holdings Inc (NASDAQ:ALXO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ALXO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • ALX Oncology Expands Equity Incentive Plan by 1.3M Shares, Increasing Potential Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$101.69M
Diluted EPS
-$1.90
Op. Cash Flow
-$84.14M
Free Cash Flow
-$84.35M
Operating Income
-$104.02M
Cash & Equivalents
$16.37M
Total Debt
$9.75M
Debt / Equity
0.38×
Shares Outstanding
54.39M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-098454
$0.994 -2.55% today
52-week range · as of 2026-10-15 $0.8617 – $2.66
Market cap
$137.03M
Volume
997.7K (0.8× avg)
3-mo avg 1.3M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALXO - Filings & News (Page 2)

ALXO
Jan 21, 2026, 4:43 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.31
Real-time Price: $0.994 info
Change: -$0.3184 (-24%) info
Market Cap: $137.031M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets